


Patient-Specific QA: Challenges and Opportunities

Moyed Miften, Ph.D.
Professor and Chief Physicist

*Department of Radiation Oncology
University of Colorado School of Medicine*



Technology and Methods Evolve



Patient-Specific QA Classification

- Measurement (most common and considered the gold standard)
 - ArcCheck, Delta4, Octavius, EPID....etc
- Computational
 - Logfile
 - MU checks
- Hybrid
 - Dose reconstruction


Patient-Specific QA: Current Paradigm

- Plan is computed on a phantom to calculate dose in the QA measurement geometry.
- Phantom is irradiated under the same conditions to measure the dose.
- Calculations and measurements are compared and approved or rejected using the institution's criteria for agreement.
- QA is performed before treatment.



Patient-Specific QA: Challenges

- Phantom-based QA and patient dose distributions are different due to their differing geometries.
- Phantom QA plan does not check for errors arise from
 - TPS management of heterogeneities
 - segmentation errors
 - patient positioning misalignments or patient anatomy changes



Patient-Specific QA: Challenges

- Analysis of dose difference from Perpendicular Composite delivery/integrated transit planar dosimetry is limited.
 - Requires much time and experience
 - Does not correlate well with anatomy changes in the patient
 - Dose differences can average out based on the arc trajectory, resulting in minor or no indication of potential errors




Ideally.....

- Dose comparison would be in patient geometry
- Dose criteria would be customized for each organ and the dose level found in that organ in order detect clinically relevant errors.
 - Tumor dose tolerance specification might be 3%, while a looser criterion of 10% might be acceptable to muscle receiving 10 Gy.
 - The spatial accuracy requirement might be 2 mm at the edge of the spinal cord, but 5 mm or more in the muscle.

Technologies are becoming more reliable so why more R&D

- Rate of complex radiation treatments are rapidly increasing
- Linacs and their performance are NOT static
- Patient anatomy changes during treatment
- Need to detect clinically relevant errors



QA Practice Future Directions

- Perform QA before treatment and during treatment
- Refine the QA analysis tools and apply in a robust manner
- Dose distributions comparison in patients
- Utilize the power of data




Dose Reconstruction Methods

Novel QA Methods

- Plan Dose Perturbation
- Fluence-Based Forward Algorithms
- 3D In Vivo Dosimetry
 - Time Resolved
- Machine Learning

Plan Dose Perturbation




- Difference between the measured and planned dose in phantom perturb the TPS calculated patient dose to create a corrected 3D dose distribution in patient.
- Forward calculation algorithm is not required. PDP uses measurements to create the perturbation matrix for correcting the plan dose.

Forward Algorithms

- Patient-specific beams are delivered to the detector typically in the absence of a phantom or patient.
- Planar measurements are corrected for the response of the detector and then used as the input fluence map.
- CT data along with a forward calculation algorithm is used reconstruct the dose in patient.
- Requires an independent dose calculation platform but also can be performed using the TPS algorithm.


3D In Vivo Dosimetry

- EPID images collected during patient treatment are used to reconstruct dose in the patient.
- Measured transmission fluence corrected for EPID response and scatter from patient.
- Primary fluence is deconvolved, backprojected and then forward transported through the patient anatomy (CT or CBCT).
- 3D calculated patient dose compared with the treatment plan.



Wouter van Elmpt et al, IJROBP 2009


Lung Patient Tumor Shrinkage



Courtesy of Jennifer Hamilton

Time Resolved In Vivo Dosimetry


- Analysis of VMAT at various time points does not suffer from the same geometrical shortcomings of planar integrated methods.
- Detect dose delivery deviations caused by patient anatomical changes.
- CT or CBCT and 2D planar pre-treatment dose, and plan parameters are used.



LCG Persoon et al, TCRT 2015, M. Podesta et al, PMB 2014

Time Resolved In Vivo Dosimetry

- Control point (CP) by control point planar dose during treatment are compared to the CP-by-CP transit dose predictions based on planning CT.
- Provides dose comparison and the magnitude of gamma failure as function of gantry angle with the percentage γ pixels $>+1$ or <-1 .




The slide contains a figure with four sub-panels:

- Top-left: 'Control 1' and 'Control 2' showing planar dose maps.
- Top-right: 'Integrated 2D γ ' showing a color-coded gamma failure map with a scale from -3 to 3.
- Bottom-left: 'Time resolved γ failure' showing a polar plot of gamma failure percentage vs gantry angle.
- Bottom-right: 'DVH' showing a graph of Dose (Gy) vs Volume (cc) for PTV and PTV (OBT) to B.

LCG Persoon et al, TCRT 2015

H&N Patient Weight Loss




The slide contains a figure with four sub-panels:

- Top-left: 'CT' showing a cross-sectional CT scan of the head and neck.
- Top-middle: 'CBCT # 19' showing a cross-sectional CBCT scan.
- Top-right: 'Integrated 2D γ ' showing a color-coded gamma failure map.
- Bottom-left: 'Time resolved γ failure' showing a polar plot of gamma failure percentage vs gantry angle.
- Bottom-right: 'DVH' showing a graph of Dose (Gy) vs Volume (cc) for PTV and PTV (OBT) to B.

LCG Persoon et al, TCRT 2015

Pelvic Patient




The slide contains a figure with four sub-panels:

- Top-left: 'CT' showing a cross-sectional CT scan of the pelvis.
- Top-middle: 'CBCT # 3' showing a cross-sectional CBCT scan.
- Top-right: 'Integrated 2D γ ' showing a color-coded gamma failure map.
- Bottom-left: 'Time resolved γ failure' showing a polar plot of gamma failure percentage vs gantry angle.
- Bottom-right: 'DVH' showing a graph of Dose (Gy) vs Volume (cc) for PTV, PTV (OBT) to B, Rectum, Rectum (OBT) to B, Anus, and Anus (OBT) to B.

LCG Persoon et al, TCRT 2015

Machine Learning Virtual QA


- Predict IMRT QA results using machine learning (ML).
- Characterize each plan by metrics that describe different aspects of plan complexity and may lead to dose differences.
- A regression algorithm is trained to learn the relation between the plan characteristics and each passing rate.



G. Valdes et al., Med Phys 2016, JACMP 2017

ML QA Results

- Metrics that described the passing rates with the higher the value of these metrics, the worse the passing rates
 - MU factor (MU per Gy),
 - Small aperture score and irregularity factor
 - Fraction of the plan delivered at the corners of a 40 x 40 cm field.



G. Valdes et al., Med Phys 2016

Conclusions

- Accurate and efficient QA methods that provide dose difference information in patients are becoming viable tools.
- In Vivo dosimetry QA ensures treatment delivery accuracy with respect to patient anatomy changes and setup errors.
- Time resolved QA for VMAT is a novel treatment monitoring tool due to its time-resolved measurement of dose delivery.
- While software-based QA tools are becoming more reliable, measurement will continue to be the gold standard.

Thank You



CU Anschutz Medical Campus
